



GEMABIOTECH

Founded in 1998, GEMABIOTECH is a private biotechnology company with headquarters in Buenos Aires, Argentina. The company is focused on the development, production, purification, characterization and testing of human cytokines grown in serum-free mediums for therapeutic use. It is also involved in the discovery and development of novel delivery systems for biopharmaceuticals.

GEMABIOTECH sets itself apart through distinctive and traceable protocols in quality control as well as through its eukaryotic cell bank generation by the creation of a master cell bank from single cell derived clones. Also, the broad and international experience of its scientists as well as GEMABIOTECH's proprietary state-of-the-art technology allows the company to elaborate products of the highest quality, work in all kinds of cell cultures such as CHO, E Coli, BHK and yeast cells, and be the first to market with second generation biogenerics.

Protocols in quality control include:

- Accurate molecular weight measurement (Maldi Tof)
- Percent content of Isoforms Determination (Capillary Zone Electrophoresis)
- Mass Spectrometry for Isoform distribution studies

GEMABIOTECH was originally a pioneer in the use of genomics, proteomics and bioinformatics, for the systematic study of all human genes and its main pathways. Together with Accelrys (formerly, MSI), Hyseq Inc., Cytoclonal Pharmaceuticals Inc. and Genaissance Pharmaceuticals, Gema co-founded the Functional Genomic Consortium (USA), an organization devoted to developing new bioinformatics tools for the prediction of protein structures and for 3-D modeling.